Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia

Emanuel Schwarz*, Rauf Izmailov, Michael Spain, Anthony Barnes, James P. Mapes, Paul C. Guest, Hassan Rahmoune, Sandra Pietsch, F. Markus Leweke, Matthias Rothermundt, Johann Steiner, Dagmar Koethe, Laura Kranaster, Patricia Ohrmann, Thomas Suslow, Yishai Levin, Bernhard Bogerts, Nico van Beveren, George McAllister, Natalya WeberDavid Niebuhr, David Cowan, Robert H. Yolken, Sabine Bahn

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

157 Scopus citations


We describe the validation of a serum-based test developed by Rules-Based Medicine which can be used to help confirm the diagnosis of schizophrenia. In preliminary studies using multiplex immunoassay profiling technology, we identified a disease signature comprised of 51 analytes which could distinguish schizophrenia (n = 250) from control (n = 230) subjects. In the next stage, these analytes were developed as a refined 51-plex immunoassay panel for validation using a large independent cohort of schizophrenia (n = 577) and control (n = 229) subjects. The resulting test yielded an overall sensitivity of 83% and specificity of 83% with a receiver operating characteristic area under the curve (ROC-AUC) of 89%. These 51 immunoassays and the associated decision rule delivered a sensitive and specific prediction for the presence of schizophrenia in patients compared to matched healthy controls.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalBiomarker Insights
Issue number5
StatePublished - 2010
Externally publishedYes


  • Diagnosis
  • Schizophrenia
  • Serum-based test


Dive into the research topics of 'Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia'. Together they form a unique fingerprint.

Cite this